Table 1 Demographic and clinical patient characteristics

Age

59.7 ± 10.8

Gender, female

100 (67)

Disease duration (year)

12.2 ± 9.1

Biological treatment duration >2 years

120 (80)

Patient measures

 Function (0–10)

2.6 ± 1.8 (total; n = 150 patients)

4.2 ± 1.8 (DAS28-ESR >5.1; n = 22)

3.2 ± 1.5 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)

2.4 ± 1.7 (DAS28-ESR ≥2.6 to <3.2; n = 31)

1.4 ± 1.4 (DAS28-ESR <2.6; n = 47)

 Pain (0–10)

4.4 ± 2.5 (total; n = 150 patients)

6.6 ± 1.4 (DAS28-ESR >5.1; n = 22)

4.8 ± 2.2 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)

4.1 ± 2.3 (DAS28-ESR ≥2.6 to <3.2; n = 31)

3.1 ± 2.4 (DAS28-ESR <2.6; n = 47)

 Patient global estimate VAS (0–10)

4.7 ± 2.5 (total; n = 150 patients)

6.8 ± 1.2 (DAS28-ESR >5.1; n = 22)

5.2 ± 2.3 (DAS28-ESR ≥3.2 to ≤5.1; n = 50)

4.2 ± 2.3 (DAS28-ESR ≥2.6 to <3.2; n = 31)

3.6 ± 2.6 (DAS28-ESR <2.6; n = 47)

Disease activity indices

 DAS28-ESR

3.4 ± 1.4

 RAPID3

11.7 ± 6.2

Medications

 Etanercept (Enbrel)

61 (40.7)

 Adalimumab (Humira)

53 (35.3)

 Tocilizumab (Roactemra)

21 (14)

 Abatacept (Orencia)

8 (5.3)

 Infliximab (Remicade)

6 (4)

 Certolizumab (Cimzia)

1 (0.7)

 Methotrexate weekly (5–25 mg) combination therapy

34 (23)